Patient Capital Management, LLC

BALTIMORE, MD · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 12, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.98B2026 Q3+ $167.2M options (notional, not included)
Positions41
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.50.4%

Patient Capital Management, LLC reported 41 positions worth $2.98B as of September 30, 2026 (13F filed November 12, 2026). Largest holding: RPRX (6.3%). Biggest move: new buy META PLATFORMS INC ($124.4M).

10 / 41 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 RPRXRoyalty Pharma$199.7M6.35%3,422,067——+17.4%
▸ 2 CCitigroup$179.9M5.72%1,389,556——-6.3%
▸ 3 GOOGLAlphabet$178.4M5.67%518,480——-17.5%
▸ 4 AMZNAmazon$168.7M5.36%677,117——+3.5%
▸ 5 NVDANVIDIA$162.1M5.15%709,927——-31.6%
▸ 6 UNHUnitedHealth$156.3M4.97%425,852——+12.2%
▸ 7 PGENPrecigen$153.7M4.88%17,950,104——-47.0%
▸ 8 METAMeta Platforms$131.2M4.17%180,982——-13.6%
▸ 9 QXOQXO$127.8M4.06%10,932,468——+2.7%
▸ 10 CHYMChime Financial$126.0M4.01%4,730,900——+28.7%

Pro Feature

The remaining 31 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Patient Capital Management, LLC hold as of Q3 2026?

Patient Capital Management, LLC reported 41 positions worth $2.98B in its Q3 2026 13F filing. Largest positions: RPRX (6.3%), C (5.7%), GOOGL (5.7%), AMZN (5.4%) and NVDA (5.2%).

What did Patient Capital Management, LLC buy in Q3 2026?

New positions: META PLATFORMS INC, AVGO, IDRV and XHB. Added to: QXO, CHYM, ADBE, META and FBTC (6 in all).

What did Patient Capital Management, LLC sell in Q3 2026?

Reduced: JD, CVS, PPLI, DAL and FISV (27 in all). Sold out entirely: ILMN, PLAY and SPY.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.